Moreover, the above-mentioned pre-analytical and analytical conditions may have major impacts on accurate identification of lower HER2 cases, not to mention the uncertainty of whether HER2 0 BC will respond to T-DXd. This evidence concerns the gene ERBB2 and breast cancer.